Build the readiness picture
A treatment plan is ready only when its clinical owner, access requirements, product supply, consent and monitoring fit together. A single “yes” from one part of the process cannot settle all the others.
Before you start: Clinical trials versus expanded access identifies the route and responsible participants. Drug labeling and off-label use keeps regulatory status separate from clinical suitability.
Where this step sits
You have identified a pathway and checked a trial opportunity when one applies. This final lesson gathers the remaining questions into a readiness picture you can discuss with the responsible team.
Give each gate an owner
Think of a treatment plan as a relay with several handoffs. The treating clinician assesses alternatives and risk. A supplier decides whether it can provide product and supporting information. The site or institution decides whether it can deliver and monitor the plan. Review and consent requirements depend on the pathway.
For U.S. expanded access, the Food and Drug Administration (FDA) assesses whether treatment may proceed. An institutional review board (IRB) provides the applicable review of patient protections and consent. Individual-patient pathways can use specific review procedures; emergency situations have special rules. Those details belong with the physician and responsible institution.
The practical questions stay concrete: Who is prescribing or sponsoring the request? Who receives and stores product? Who administers it? Where does the patient go if a serious problem occurs? Who records and reports adverse events? A supplier's willingness is useful, but it does not create the clinical service around the product.
Use a readiness ledger
| Gate | Question for the responsible team |
|---|---|
| Clinical rationale | Why consider this treatment, and which alternatives remain? |
| Exact product | What formulation, dose, route and schedule are proposed? |
| Supply | Has the supplier agreed, and is usable product available? |
| Pathway and review | What submissions, permissions and institutional reviews apply? |
| Consent | Are known risks, unknowns, alternatives and responsibilities clear? |
| Delivery and monitoring | Which team gives treatment, checks response and manages toxicity? |
| Time | What must happen first, and what could delay or stop the plan? |
| Costs and logistics | Which treatment, care, travel and follow-up expenses are covered? |
Record “confirmed,” “proposed,” or “unknown” beside each item. Keep the confirming person and date in the actual project record. This teaching page supplies the questions, rather than a patient's status table.
Understand the clock you are looking at
For a non-emergency single-patient Investigational New Drug (IND) application, FDA states that treatment can begin 30 days after receipt or earlier if FDA tells the physician it may proceed, with applicable reviews and informed consent. That clock concerns the regulatory submission. It does not include every step needed to prepare a patient-specific product or arrange care.
Emergency expanded access can receive rapid authorization before the later written submission. The emergency pathway has its own requirements and follow-up. It is not a way to label every time-sensitive plan as an emergency.
Ask which clock a quoted timeline refers to: supplier review, product manufacture, FDA review, institutional review, shipping, or clinical scheduling. Some tasks may run in parallel. Others depend on earlier answers. The team needs a plan for delays as well as an ideal schedule.
Worked example: a fictional “ready next week” message
Mara receives a message saying a personalized product could be “ready next week.” Her physician asks whether that means the product is manufactured, the proposed treatment is authorized, or the site can give the first dose.
The supplier confirms only that manufacture could finish. Institutional review, the treatment plan and monitoring arrangements are still being discussed. The message describes one promising milestone, rather than complete treatment readiness.
Mara can now ask a better question: “Which gates are complete, which depend on other steps, and who owns each remaining answer?” This keeps the conversation calm and specific. It also prevents a tentative timeline from becoming a promised start date.
Consent is an ongoing conversation
Informed consent explains the intervention, expected procedures, potential benefits, known harms, uncertainty and alternatives. It also covers what participation or treatment involves. Signing a form does not make the benefit known.
Ask for information in language you can understand. Questions can continue after a form is signed. In trials, participants may leave the study; the team should explain how to do so safely and what follow-up is appropriate.
Costs deserve the same clarity. Research costs, routine care and travel are different categories. A sponsor may cover some items while an insurer or patient bears others. Request a written explanation for the particular plan rather than assuming an access authorization includes payment.
What can go wrong at this step
- Product readiness becomes treatment readiness. Review, delivery and monitoring may remain unresolved.
- A regulatory clock becomes an end-to-end promise. Manufacturing and clinical scheduling have separate dependencies.
- Consent becomes evidence of effectiveness. It documents an informed choice under uncertainty.
- An access approval becomes financial coverage. Confirm the specific cost categories.
Try it
A fictional expanded-access request may proceed, but the institution has no team able to administer and monitor the product. Is the treatment ready?
Answer: No. Permission to proceed does not establish a feasible delivery and monitoring plan. The clinical team must resolve that gap before calling the treatment ready.
Explain it back
Complete: “Permission, supply and clinical readiness are separate because ____.”
One possible answer: “Each answers a different question, and the patient needs all the applicable parts to fit together.”
Takeaway
Keep access permission, usable supply, informed consent and clinical readiness visible as separate gates.
Next: Bring the readiness ledger to the responsible clinical or study team, or return to the guide map to revisit an uncertain route.
Sources and scope
U.S. source check: October 9, 2026. The product and timeline example is fictional. No end-to-end preparation time or individual authorization is promised. Expert and learner review pending.
- FDA: how physicians request single-patient expanded access — non-emergency and emergency timing.
- FDA: expanded access information for IRBs — responsibility, review, consent and monitoring.
- NCI: clinical trial safety and consent — ongoing consent and participant rights.
- NCI: who pays for clinical trials — routine care, research and practical costs.